5-Amino-1MQ vs AOD-9604

5-Amino-1MQ

5-Amino-1MQ is a small quinolinium molecule, not a peptide, designed to inhibit the enzyme nicotinamide N-methyltransferase (NNMT). It came out of medicinal-chemistry work on a series of methylquinolinium analogues screened against that enzyme, which methylates nicotinamide and is expressed at high levels in liver and fat tissue. Interest in NNMT grew once it was linked to the balance of NAD+ and of methyl donors inside cells. Published work on 5-Amino-1MQ is preclinical: enzyme assays, cultured fat cells and diet-induced obese mouse models. Human data are very limited, and its selectivity and behaviour in the whole organism are not well characterised.

AOD-9604

AOD-9604 is a synthetic peptide based on the C-terminal segment of human growth hormone, with a tyrosine at its N-terminus and a disulfide bond. It was designed to test the idea that this short region carries some of growth hormone's activity on fat metabolism separately from the rest of the molecule. Work on it began with rodent studies of fat cells and whole-animal lipid metabolism, and the peptide later entered human clinical trials, whose published record is sparse. A smaller body of animal work has looked at cartilage in joint injury models. Unlike full-length growth hormone, it is not regarded as a growth hormone receptor agonist, which shapes how its reported activity is interpreted.

How 5-Amino-1MQ acts

NNMT transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine. 5-Amino-1MQ is thought to occupy the enzyme's nicotinamide site and compete with the natural substrate. Because the reaction consumes both SAM and nicotinamide, a precursor recycled into NAD+ through the salvage pathway, inhibitors of this kind have been used in cultured adipocytes and rodent studies to examine how NNMT activity relates to intracellular NAD+ and SAM levels and to lipid handling in fat cells. How selective the compound is across other methyltransferases, and how it is distributed and cleared in animals, has been only partly described.

How AOD-9604 acts

AOD-9604 has been reported not to bind the growth hormone receptor with meaningful affinity and not to act through the IGF-1 axis, so its proposed actions differ from those of the whole hormone. Studies in isolated rodent fat cells and in obese mice examined lipolysis and lipogenesis, and some of that work implicated beta-3 adrenergic receptor pathways. A receptor that binds the fragment directly has not been identified. The cartilage studies used animal joint injury models and measured markers of cartilage matrix, and no mechanism for those observations has been established. Overall, the mechanistic literature is small and comes from a limited number of groups.

The records side by side

• Type: 5-Amino-1MQ, Small molecule (quinolinium cation); AOD-9604, Modified hGH fragment (176-191)
• Length: 5-Amino-1MQ, not recorded; AOD-9604, 16 amino acids
• Molecular weight: 5-Amino-1MQ, 159.21 g/mol; AOD-9604, 1815.1 g/mol
• Molecular formula: 5-Amino-1MQ, C10H11N2+; AOD-9604, C78H123N23O23S2

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.